These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 35953814)
1. Mitochondrial ROS drive resistance to chemotherapy and immune-killing in hypoxic non-small cell lung cancer. Salaroglio IC; Belisario DC; Akman M; La Vecchia S; Godel M; Anobile DP; Ortone G; Digiovanni S; Fontana S; Costamagna C; Rubinstein M; Kopecka J; Riganti C J Exp Clin Cancer Res; 2022 Aug; 41(1):243. PubMed ID: 35953814 [TBL] [Abstract][Full Text] [Related]
2. TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer. Akman M; Monteleone C; Doronzo G; Godel M; Napoli F; Merlini A; Campani V; Nele V; Balmas E; Chontorotzea T; Fontana S; Digiovanni S; Barbu FA; Astanina E; Jafari N; Salaroglio IC; Kopecka J; De Rosa G; Mohr T; Bertero A; Righi L; Novello S; Scagliotti GV; Bussolino F; Riganti C J Exp Clin Cancer Res; 2024 Aug; 43(1):219. PubMed ID: 39107857 [TBL] [Abstract][Full Text] [Related]
3. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342 [TBL] [Abstract][Full Text] [Related]
4. Allicin Overcomes Hypoxia Mediated Cisplatin Resistance in Lung Cancer Cells through ROS Mediated Cell Death Pathway and by Suppressing Hypoxia Inducible Factors. Pandey N; Tyagi G; Kaur P; Pradhan S; Rajam MV; Srivastava T Cell Physiol Biochem; 2020 Aug; 54(4):748-766. PubMed ID: 32809300 [TBL] [Abstract][Full Text] [Related]
5. Hypoxia-induced ROS promotes mitochondrial fission and cisplatin chemosensitivity via HIF-1α/Mff regulation in head and neck squamous cell carcinoma. Wu K; Mao YY; Chen Q; Zhang B; Zhang S; Wu HJ; Li Y Cell Oncol (Dordr); 2021 Oct; 44(5):1167-1181. PubMed ID: 34460078 [TBL] [Abstract][Full Text] [Related]
6. Stabilization of hypoxia-inducible factor-1alpha protein in hypoxia occurs independently of mitochondrial reactive oxygen species production. Chua YL; Dufour E; Dassa EP; Rustin P; Jacobs HT; Taylor CT; Hagen T J Biol Chem; 2010 Oct; 285(41):31277-84. PubMed ID: 20675386 [TBL] [Abstract][Full Text] [Related]
7. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway. Gong T; Cui L; Wang H; Wang H; Han N J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734 [TBL] [Abstract][Full Text] [Related]
9. Mitochondrial NDUFA4L2 protein promotes the vitality of lung cancer cells by repressing oxidative stress. Meng L; Yang X; Xie X; Wang M Thorac Cancer; 2019 Apr; 10(4):676-685. PubMed ID: 30710412 [TBL] [Abstract][Full Text] [Related]
10. Hypoxia-inducible factor 1α (HIF-1α) and reactive oxygen species (ROS) mediates radiation-induced invasiveness through the SDF-1α/CXCR4 pathway in non-small cell lung carcinoma cells. Gu Q; He Y; Ji J; Yao Y; Shen W; Luo J; Zhu W; Cao H; Geng Y; Xu J; Zhang S; Cao J; Ding WQ Oncotarget; 2015 May; 6(13):10893-907. PubMed ID: 25843954 [TBL] [Abstract][Full Text] [Related]
11. Mitochondrial reactive oxygen species mediates nicotine-induced hypoxia-inducible factor-1α expression in human non-small cell lung cancer cells. Guo L; Li L; Wang W; Pan Z; Zhou Q; Wu Z Biochim Biophys Acta; 2012 Jun; 1822(6):852-61. PubMed ID: 22349311 [TBL] [Abstract][Full Text] [Related]
12. Eukaryotic initiation factor 5A2 mediates hypoxia-induced autophagy and cisplatin resistance. Xu G; Chen H; Wu S; Chen J; Zhang S; Shao G; Sun L; Mu Y; Liu K; Pan Q; Li N; An X; Lin S; Chen W Cell Death Dis; 2022 Aug; 13(8):683. PubMed ID: 35931669 [TBL] [Abstract][Full Text] [Related]
13. Hypoxia-induced lncRNA-AC020978 promotes proliferation and glycolytic metabolism of non-small cell lung cancer by regulating PKM2/HIF-1α axis. Hua Q; Mi B; Xu F; Wen J; Zhao L; Liu J; Huang G Theranostics; 2020; 10(11):4762-4778. PubMed ID: 32308748 [No Abstract] [Full Text] [Related]
14. Propofol suppresses LPS-induced nuclear accumulation of HIF-1α and tumor aggressiveness in non-small cell lung cancer. Yang N; Liang Y; Yang P; Ji F Oncol Rep; 2017 May; 37(5):2611-2619. PubMed ID: 28426124 [TBL] [Abstract][Full Text] [Related]
15. SIRT3 Regulates the ROS-FPR1/HIF-1α Axis under Hypoxic Conditions to Influence Lung Cancer Progression. Huang B; Ding J; Guo H; Wang H; Xu J; Zheng Q; Zhou L Cell Biochem Biophys; 2023 Dec; 81(4):813-821. PubMed ID: 37747648 [TBL] [Abstract][Full Text] [Related]
16. HIF-1-dependent heme synthesis promotes gemcitabine resistance in human non-small cell lung cancers via enhanced ABCB6 expression. Xiang L; Wang Y; Lan J; Na F; Wu S; Gong Y; Du H; Shao B; Xie G Cell Mol Life Sci; 2022 Jun; 79(6):343. PubMed ID: 35661930 [TBL] [Abstract][Full Text] [Related]
17. Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1α mediated XPC transcription. Liu Y; Wang X; Li W; Xu Y; Zhuo Y; Li M; He Y; Wang X; Guo Q; Zhao L; Qiang L Oncogene; 2020 Nov; 39(45):6893-6905. PubMed ID: 32978517 [TBL] [Abstract][Full Text] [Related]
18. Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR. Meng S; Wang G; Lu Y; Fan Z Lung Cancer; 2018 Jul; 121():82-90. PubMed ID: 29858032 [TBL] [Abstract][Full Text] [Related]
19. Cycling hypoxia increases U87 glioma cell radioresistance via ROS induced higher and long-term HIF-1 signal transduction activity. Hsieh CH; Lee CH; Liang JA; Yu CY; Shyu WC Oncol Rep; 2010 Dec; 24(6):1629-36. PubMed ID: 21042761 [TBL] [Abstract][Full Text] [Related]
20. Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1α. Biziotis OD; Tsakiridis EE; Ali A; Ahmadi E; Wu J; Wang S; Mekhaeil B; Singh K; Menjolian G; Farrell T; Abdulkarim B; Sur RK; Mesci A; Ellis P; Berg T; Bramson JL; Muti P; Steinberg GR; Tsakiridis T Mol Oncol; 2023 Nov; 17(11):2235-2256. PubMed ID: 37584455 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]